AIDS vaccine candidates based on recombinant vectors may ultimately fail to provide adequate protection against HIV-1 in ongoing clinical trials. Live, attenuated vaccines afford more reliable protection in animals, but justifiable concerns about their safety will likely preclude their use in humans for the foreseeable future. Thus, the search continues for an AIDS vaccine that optimizes both safety and efficacy. One promising approach is the use of lentiviruses that are limited to a single cycle of infection. We have developed a unique system for producing strains of SIV that are limited to one round of infection as a non-replicating vaccine approach. Cells infected with this single-cycle SIV (scSIV) express all of the viral gene products except for Pol and release immature virus particles that cannot complete subsequent rounds of infection. In preliminary studies, rhesus macaques immunized with scSIV made antibody and T cell responses to multiple viral antigens. Following an intravenous challenge with SIVmac239, a strain that is notoriously difficult to protect against by vaccination, these animals also exhibited significant reductions in both acute and chronic phase viral loads relative to unvaccinated control animals. We now propose to more fully evaluate the extent of protection that may be achieved by this novel vaccine approach.
In specific aim 1, we will test two different scSIV vaccine regimens to compare the effects of frequency versus dose of inoculation on the development of virus-specific immune responses and the ability to contain infection after a pathogenic SIV challenge.
In specific aim 2, we will test the hypothesis that the induction of neutralizing antibodies by envelope-modified strains of scSIV can enhance protection.
In specific aim 3, we will determine if the site of scSIV immunization influences the mucosal homing properties of virus-specific T cell responses and the ability to protect against a mucosal SIV challenge. Associations between immune responses elicited by scSIV and the outcome of challenge will be analyzed for each specific aim to reveal potential mechanisms of protection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI063993-01
Application #
6892439
Study Section
Special Emphasis Panel (ZRG1-VACC (01))
Program Officer
Warren, Jon T
Project Start
2005-03-15
Project End
2009-02-28
Budget Start
2005-03-15
Budget End
2006-02-28
Support Year
1
Fiscal Year
2005
Total Cost
$604,483
Indirect Cost
Name
Harvard University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Alpert, Michael D; Heyer, Lisa N; Williams, David E J et al. (2012) A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J Virol 86:12039-52
Alpert, Michael D; Harvey, Jackson D; Lauer, W Anderson et al. (2012) ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 8:e1002890
Colantonio, Arnaud D; Bimber, Benjamin N; Neidermyer Jr, William J et al. (2011) KIR polymorphisms modulate peptide-dependent binding to an MHC class I ligand with a Bw6 motif. PLoS Pathog 7:e1001316
Gupta, Sachin; Termini, James M; Niu, Liguo et al. (2011) Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines. Retrovirology 8:39
Specht, Anke; Telenti, Amalio; Martinez, Raquel et al. (2010) Counteraction of HLA-C-mediated immune control of HIV-1 by Nef. J Virol 84:7300-11
Alpert, Michael D; Rahmberg, Andrew R; Neidermyer, William et al. (2010) Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge. J Virol 84:10748-64
Evans, David T; Serra-Moreno, Ruth; Singh, Rajendra K et al. (2010) BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 18:388-96
Salisch, Nadine C; Kaufmann, Daniel E; Awad, Amany S et al. (2010) Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J Immunol 184:476-87
Jia, Bin; Serra-Moreno, Ruth; Neidermyer, William et al. (2009) Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5:e1000429
Jia, Bin; Ng, Sharon K; DeGottardi, M Quinn et al. (2009) Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239. PLoS Pathog 5:e1000272

Showing the most recent 10 out of 13 publications